Octreotide

产品说明书

Print
Chemical Structure| 83150-76-9 同义名 : Octreotide游离态 ;SMS 201-995
CAS号 : 83150-76-9
货号 : A813598
分子式 : C49H66N10O10S2
纯度 : 99%
分子量 : 1019.239
MDL号 : MFCD08277638
存储条件：

Pure form Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 :

H2O: 100 mg/mL(98.11 mM)，配合低频超声助溶
动物实验配方：
生物活性
描述 Octreotide is a somatostatin analog that binds to the somatostatin receptor, mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide improved hepatic glycogenesis and decreased FPG (fasting plasma glucose) concentration in rats with HFD (high fat diet)‑induced obesity[3]. Octreotide was shown to reduce the perception of rectal distension without affecting motor pathways or local rectal reflexes[4]. Octreotide improves secretory diarrhoea resulting from neuroendocrine tumours, intestinal infections in AIDS patients, and intestinal graft v host disease[5]. Octreotide was used safely as an adjunctive therapy for the treatment of chylothorax and chylous ascites in neonates[6]. In comparison to the saline-treated group, allodynia was partially attenuated by octreotide, though this was almost completely reversed by morphine. Octreotide has an antinociceptive effect, which was less than morphine[7].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00742339 Cirrhosis Hep... 展开 >>atorenal Syndrome 收起 << Phase 2 Phase 3 Terminated(Decision of indepen... 展开 >>dent monitoring committee Risk of non-response to treatment significantly higher in midodrine group than in terlipressin group.) 收起 << - Italy ... 展开 >> Dept. of Clinical and Experimental Medicine, University of Padova Padova, Italy, 35100 收起 <<
NCT00376064 Acromegaly Phase 4 Completed - Germany ... 展开 >> Novartis Investigative Site Aachen, Germany Novartis Investigative Site Berlin, Germany Novartis Investigative Site Bochum, Germany Novartis Investigative Site Erlangen, Germany Novartis Investigative Site Essen, Germany Novartis Investigative Site Greifswald, Germany Novartis Investigative Site Heidelberg, Germany Novartis Investigative Site Koln, Germany Novartis Investigative Site Leipzig, Germany Novartis Investigative Site Marburg, Germany Novartis Investigative Site Muenchen, Germany Novartis Investigative Site Oldenburg, Germany Novartis Investigative Site Regensburg, Germany Novartis Investigative Site Tubingen, Germany Novartis Investigative Site Ulm, Germany Novartis Investigative Site Wurzburg, Germany 收起 <<
NCT00595140 Acromegaly Phase 4 Completed - Germany ... 展开 >> Medizinische Klinik - Innenstadt of the University of Munich Munich, Germany, 80336 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

0.98mL

0.20mL

0.10mL

4.91mL

0.98mL

0.49mL

9.81mL

1.96mL

0.98mL
参考文献

[1]Deng C, Deng B, et al. Efficacy of long-acting release octreotide for preventing chemotherapy-induced diarrhoea: protocol for a systematic review. BMJ Open. 2017 Jun 21;7(6):e014916.

[2]Raynor K, Murphy WA, et al. Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. Mol Pharmacol. 1993 Jun;43(6):838-44.

[3]Wang XX, Ye T, Li M, Li X, Qiang O, Tang CW, Liu R. Effects of octreotide on hepatic glycogenesis in rats with high fat diet‑induced obesity. Mol Med Rep. 2017 Jul;16(1):109-118

[4]Owyang C. Octreotide in gastrointestinal motility disorders. Gut. 1994;35(3 Suppl):S11-4

[5]Farthing MJ. Octreotide in the treatment of refractory diarrhoea and intestinal fistulae. Gut. 1994;35(3 Suppl):S5-10

[6]Zaki SA, Krishnamurthy MB, Malhotra A. Octreotide Use in Neonates: A Case Series. Drugs R D. 2018 Sep;18(3):191-198

[7]Singh P, Ray SB. Comparison of Antinociceptive Effect of Octreotide With Morphine in a Rat Model of Acute Inflammatory Pain. Ann Neurosci. 2021 Jan;28(1-2):13-20